HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.5%

Neg 0% Neu 92.5% Pos 0%

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.